Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-04-014100PMID 16931626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies.

  2008cited by this paper
• Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes

  2006cited by this paper
• Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

  2006cited by this paper
• Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• T-cell alloreactivity in hematopoietic stem cell transplantation.

  2005cited by this paper
• Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

  2005cited by this paper
• Toward improved immunocompetence of adoptively transferred CD8+ T cells.

  2005cited by this paper
• Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

  2004cited by this paper
• CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

  2004cited by this paper
• Molecules and mechanisms of the graft-versus-leukaemia effect

  2004cited by this paper
• Functional assessment and specific depletion of alloreactive human T cells using flow cytometry.

  2004cited by this paper
• HLA matching in allogeneic stem cell transplantation

  2004influential reference
• Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.

  2004cited by this paper
• Minor histocompatibility antigens in human stem cell transplantation.

  2003cited by this paper
• Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences

  2003cited by this paper
• Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

  2003cited by this paper
• Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.

  2003cited by this paper
• Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.

  2002cited by this paper
• Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential.

  2002cited by this paper
• Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

  2002cited by this paper
• Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study.

  2002cited by this paper
• The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

  2002cited by this paper
• The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.

  2002cited by this paper
• P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.

  2002cited by this paper
• Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.

  2002cited by this paper
• ReviewPathways of Apoptosis in Lymphocyte Development , Homeostasis , and Disease

  2002cited by this paper
• Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.

  2002cited by this paper
• Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions

  2002cited by this paper
• Haematopoietic cell transplantation as immunotherapy

  2001cited by this paper
• Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.

  2001cited by this paper
• The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

  2001cited by this paper
• Depletion of alloreactive donor T cells using immunomagnetic cell selection

  2000cited by this paper
• Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CD8+ T Cells1

  2000cited by this paper
• Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood

  2000cited by this paper
• Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft‐versus‐host disease

  1999cited by this paper
• Transplantation of anergic histoincompatible bone marrow allografts.

  1999cited by this paper
• Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.

  1999cited by this paper
• Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

  1999cited by this paper
• Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis

  1999cited by this paper
• Transplantation of Megadoses of Purified Haploidentical Stem Cells

  1999cited by this paper
• Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.

  1998cited by this paper
• Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

  1998cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• EFFECT OF MATCHING OF CLASS I HLA ALLELES ON CLINICAL OUTCOME AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM AN UNRELATED DONOR

  1998cited by this paper
• Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

  1998cited by this paper
• Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation

  1997cited by this paper
• CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.

  1997cited by this paper
• Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response

  1997cited by this paper
• Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

  1997cited by this paper
• The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens.

  1997cited by this paper
• Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation.

  1996cited by this paper
• The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL

  1996cited by this paper
• Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix.

  1995cited by this paper
• ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.

  1995cited by this paper
• Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.

  1992cited by this paper
• On the nature of peptides involved in T cell alloreactivity

  1991cited by this paper
• Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

  1989cited by this paper
• Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft-infiltrating lymphocytes.

  1989cited by this paper
• cDNA sequences of two inducible T-cell genes.

  1989cited by this paper
• Frequency analysis of cytotoxic T lymphocyte precursors--possible relevance to HLA-matched unrelated donor bone marrow transplantation.

  1988cited by this paper
• Marrow transplantation from related donors other than HLA-identical siblings.

  1985cited by this paper
• Human Cytotoxic T Lymphocytes

  1985cited by this paper
• Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

  1975cited by this paper

• A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD.

  2025cites this paper
• Hole in one: CD137-ADC eliminates GVHD.

  2025cites this paper
• Recent updates on allogeneic CAR-T cells in hematological malignancies

  2024cites this paper
• Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

  2023cites this paper
• Polyfunctional donor-reactive T cells are associated with acute T-cell-mediated rejection of the kidney transplant

  2023cites this paper
• Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens

  2021cites this paper
• CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

  2021cites this paper
• Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy

  2020cites this paper
• Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer

  2019cites this paper
• T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect

  2019cites this paper
• Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

  2019cites this paper
• Photodepletion to Promote Immune Reconstitution Without Graft-Versus-Host Disease After HLA-Haploidentical Transplantation

  2018cites this paper
• The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells

  2018cites this paper
• Inhibition of cancer cell immune evasion by combined application of cytotoxic T-lymphocytes and natural killer cells

  2018cites this paper
• Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.

  2017cites this paper
• Etude des mécanismes d'action de la photochimiothérapie extracorporelle

  2017cites this paper
• Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.

  2016cites this paper
• Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy

  2016cites this paper
• Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives.

  2016cites this paper
• Adoptive Immunotherapy for Infection Control Using Antigen-Specific Donor-Derived T Cells After Transplantation

  2016cites this paper
• Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets

  2016cites this paper
• [Donor- derived CD19 chimeric antigen receptor T cells for relapsed B cell malignancies after allogeneic hematopoietic stem cell transplantations].

  2016cites this paper
• Donor-derived CD19 chimeric antigen receptor T cells

  2015cites this paper
• Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

  2015cites this paper
• Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice

  2015cites this paper
• Haploidentical HSCT: a 15-year experience at San Raffaele

  2015cites this paper
• Depletion of Alloreactive T-Cells by Anti-CD137-Saporin Immunotoxin

  2015influential citation
• Preventing stem cell transplantation-associated viral infections using T-cell therapy.

  2015cites this paper
• Abundance and specificity of influenza reactive circulating memory follicular helper and non‐follicular helper CD4 T cells in healthy adults

  2015cites this paper
• Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rγc null mice.

  2014cites this paper
• Suppression of cytomegalovirus-specific CD8+T cells by everolimus

  2014cites this paper
• MHC multimer purification of rare antigen specific T cells and direct T cell receptor isolation by single cell PCR

  2014cites this paper
• Antiviral T‐cell therapy

  2014cites this paper
• Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT

  2014cites this paper
• Преодоление иммунной толерантности как способ лечения злокачественных опухолей: новые перспективы

  2014cites this paper
• Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

  2014cites this paper
• Towards More Specificity and Effectivity in the Antileukemia Immune Response

  2014cites this paper
• New strategies for allogeneic hematopoietic stem cell transplantation with umbilical cord

  2013cites this paper
• T-cell costimulation in graft-versus-host disease and graft-versus-leukemia effect

  2013cites this paper
• antigen without requiring knowledge of epitope specificities T cells responding to + and expansion of the full repertoire of CD8 Activation-induced expression of CD137 permits detection, isolation,

  2013cites this paper
• CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

  2013cites this paper
• CD137-selektierte leukämiereaktive T-Zellen gesunder Spender zur adoptiven Immuntherapie stammzelltransplantierter Leukämiepatienten

  2013influential citation
• Novel approaches for the isolation and expansion of cytomegalovirus-specific T cells for adoptive immunotherapy

  2013cites this paper
• Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.

  2013cites this paper
• CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert

  2013cites this paper
• Activation‐induced CD137 is a fast assay for identification and multi‐parameter flow cytometric analysis of alloreactive T cells

  2013cites this paper
• Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia

  2013cites this paper
• Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion

  2013cites this paper
• Use of TK-cells in haploidentical hematopoietic stem cell transplantation

  2012cites this paper
• Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses

  2012cites this paper
• A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

  2012cites this paper
• Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.

  2012cites this paper
• TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

  2012cites this paper
• A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

  2012cites this paper
• A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

  2012cites this paper
• Simultaneous Isolation of CD8+ and CD4+ T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation

  2011cites this paper
• Alloreactive and leukemia-reactive T cells are preferentially derived from naïve precursors in healthy donors: implications for immunotherapy with memory T cells

  2011cites this paper
• Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor.

  2011cites this paper
• Allogeneic stem cell transplantation for renal cell carcinoma

  2011cites this paper
• Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

  2011cites this paper
• Redirecting (cid:1)(cid:2) T cells against cancer cells by transfer of a broadly tumor-reactive (cid:3)(cid:4) T-cell receptor

  2011cites this paper
• Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

  2011cites this paper
• In Vitro Stimulation and Expansion of Human Tumour‐Reactive CD8+ Cytotoxic T Lymphocytes by Anti‐CD3/CD28/CD137 Magnetic Beads

  2011cites this paper
• Haploidentical hematopoietic transplantation: current status and future perspectives.

  2011cites this paper
• Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation

  2010cites this paper
• Long-Term Human CD34+ Stem Cell-Engrafted Nonobese Diabetic/SCID/IL-2Rγnull Mice Show Impaired CD8+ T Cell Maintenance and a Functional Arrest of Immature NK Cells

  2010cites this paper
• Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease

  2010cites this paper
• Hematopoietic Cell Transplantation from Partially HLA-Mismatched (HLA-Haploidentical) Related Donors

  2010cites this paper
• Advances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation.

  2010cites this paper
• Adoptive Immunotherapy for Prophylaxis and Therapy of Infectious Complications After Allogeneic Hematopoietic Stem Cell Transplantation

  2010cites this paper
• Progress and prospects: graft-versus-host disease

  2010cites this paper
• Blockade of 4-1BB/4-1BB ligand interactions prevents acute rejection in rat liver transplantation.

  2010cites this paper
• Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation

  2010cites this paper
• Alloanergization in haploidentical hematopoietic stem cell transplantation

  2010cites this paper
• Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.

  2010cites this paper
• Identification and selective depletion of alloreactive T-cells for adoptive immunotherapy.

  2010cites this paper
• Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation

  2010cites this paper
• NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

  2010cites this paper
• Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand1

  2009cites this paper
• Selective allodepletion to improve anti-viral and anti-leukaemic responses after haploidentical transplantation

  2009cites this paper
• Tolerance induction by removal of alloreactive T cells: in-vivo and pruning strategies

  2009cites this paper
• Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.

  2009cites this paper
• Treatment with Soluble Fas Ligand VivoDisease-Mediating Human T Cells by Ex Selective Reduction of Graft-versus-Host

  2009cites this paper
• Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.

  2009cites this paper
• Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation.

  2009cites this paper
• Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.

  2008cites this paper
• Cytotoxic T lymphocytes as immune‐therapy in haematological practice

  2008cites this paper
• The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer

  2008cites this paper
• Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

  2008cites this paper
• A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

  2008cites this paper
• Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.

  2008cites this paper
• Selective Depletion of Alloreactive T Lymphocytes Using Patient-Derived Nonhematopoietic Stimulator Cells in Allograft Engineering

  2008cites this paper
• CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy

  2008cites this paper
• Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities

  2008cites this paper
• Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors

  2008cites this paper
• Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.

  2008cites this paper
• The Programmed Death (PD)‐1/PD‐Ligand 1 Pathway Regulates Graft‐Versus‐Host‐Reactive CD8 T Cells After Liver Transplantation

  2008cites this paper
• T-cell therapy after hematopoietic stem cell transplantation

  2007cites this paper
• Reconstitution of FOXP 3 regulatory T cells ( Tregs ) after CD 25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease

  2007cites this paper
• Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

  2007cites this paper